Brief: Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile Of Cmnd-100 In Ongoing Phase I/Iia Clinical Trial
09/02/2026 15:01
Feb 9 (Reuters) - Clearmind Medicine Inc CMND.O: CLEARMIND MEDICINE ANNOUNCES ADDITIONAL TOPLINE POSITIVE SAFETY RESULTS REINFORCING FAVORABLE PROFILE OF CMND-100 IN ONGOING PHASE I/IIA CLINICAL TRIAL CLEARMIND MEDICINE INC - ANNOUNCES POSITIVE SAFETY RESULTS FROM PHASE I/IIA TRIAL CLEARMIND MEDICINE INC - SAFETY DATA SHOW NO SERIOUS ADVERSE EVENTS IN SECOND COHORT Source text: ID:nGNX8xlZdy Further company coverage: CMND.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearmind Medicine
See all newsBrief: Clearmind Advances Dialogue With U.S. Federal Government On Psychedelic Therapies, Submitting Recommendations To FDA
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM